Meiji Yasuda Asset Management Co Ltd. decreased its holdings in shares of Exelon Co. (NASDAQ:EXC – Get Rating) by 3.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,385 shares of the company’s stock after selling 890 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Exelon were worth $1,063,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently made changes to their positions in EXC. Stock Yards Bank & Trust Co. purchased a new stake in Exelon during the second quarter valued at about $350,000. Benjamin Edwards Inc. lifted its stake in Exelon by 17.0% during the third quarter. Benjamin Edwards Inc. now owns 17,645 shares of the company’s stock valued at $661,000 after buying an additional 2,570 shares in the last quarter. Mutual of America Capital Management LLC lifted its stake in Exelon by 2.7% during the third quarter. Mutual of America Capital Management LLC now owns 137,298 shares of the company’s stock valued at $5,143,000 after buying an additional 3,651 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in Exelon during the third quarter valued at about $564,000. Finally, Summit Global Investments lifted its position in shares of Exelon by 2.0% in the second quarter. Summit Global Investments now owns 40,181 shares of the company’s stock worth $1,821,000 after purchasing an additional 770 shares in the last quarter. Institutional investors own 80.60% of the company’s stock.
Exelon Price Performance
Shares of EXC opened at $41.34 on Wednesday. The firm has a market cap of $41.10 billion, a PE ratio of 18.88, a PEG ratio of 2.58 and a beta of 0.60. The firm’s 50 day moving average price is $41.88 and its 200 day moving average price is $40.31. The company has a debt-to-equity ratio of 1.44, a quick ratio of 0.62 and a current ratio of 0.69. Exelon Co. has a twelve month low of $35.19 and a twelve month high of $50.71.
Exelon Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, March 10th. Shareholders of record on Monday, February 27th were issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend was Friday, February 24th. This is an increase from Exelon’s previous quarterly dividend of $0.34. Exelon’s dividend payout ratio (DPR) is 65.75%.
Analysts Set New Price Targets
A number of analysts have recently issued reports on EXC shares. Credit Suisse Group increased their price target on shares of Exelon from $42.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, January 23rd. Wells Fargo & Company reduced their price target on shares of Exelon from $47.00 to $45.00 in a research report on Wednesday, February 15th. BMO Capital Markets reduced their price target on shares of Exelon from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, February 15th. Finally, Morgan Stanley increased their price target on shares of Exelon from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Thursday, December 15th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.64.
About Exelon
Exelon Corp. is a utility services holding company, which engages in the energy distribution and transmission businesses. It operates through the following segments: Commonwealth Edison Company (ComEd), PECO Energy Company (PECO), Baltimore Gas and Electric Company (BGE), Potomac Electric Power Company (Pepco), Delmarva Power & Light Company (DPL), and Atlantic City Electric Company (ACE).
Further Reading
- Get a free copy of the StockNews.com research report on Exelon (EXC)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts DefendĀ
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.